UNICYCIVE THERAPEUTICS, INC. Increase (Decrease) in Prepaid Expenses, Other
UNICYCIVE THERAPEUTICS, INC. (UNCY) reported Increase (Decrease) in Prepaid Expenses, Other of $600.00 thousand for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpensesOther · last filed 2023-11-14
- UNICYCIVE THERAPEUTICS, INC. increase (decrease) in prepaid expenses, other for the quarter ending 2022-06-30 was -$362.00K.
- UNICYCIVE THERAPEUTICS, INC. increase (decrease) in prepaid expenses, other for the quarter ending 2022-03-31 was -$263.00K, a 428.75% decline year-over-year.
- UNICYCIVE THERAPEUTICS, INC. increase (decrease) in prepaid expenses, other for the quarter ending 2021-12-31 was $1.27M.
- UNICYCIVE THERAPEUTICS, INC. increase (decrease) in prepaid expenses, other for the quarter ending 2021-09-30 was $51.00K.
- UNICYCIVE THERAPEUTICS, INC. increase (decrease) in prepaid expenses, other for fiscal 2021 was $1.32M.
- UNICYCIVE THERAPEUTICS, INC. increase (decrease) in prepaid expenses, other for fiscal 2020 was -$1.00K.
| Period end | Increase (Decrease) in Prepaid Expenses, Other 3 month | Increase (Decrease) in Prepaid Expenses, Other 6 month | Increase (Decrease) in Prepaid Expenses, Other 9 month | Increase (Decrease) in Prepaid Expenses, Other 9 month as first filed | Increase (Decrease) in Prepaid Expenses, Other 12 month |
|---|---|---|---|---|---|
| 2023-09-30 | $600.00K 10-Q · filed 2023-11-14 | ||||
| 2022-06-30 | -$362.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$625.00K 10-Q · filed 2022-08-15 | $642.00K derived: sum of 3 quarters · filed 2022-08-15 | $693.00K derived: sum of 4 quarters · filed 2022-11-14 | |
| 2022-03-31 | -$263.00K 10-Q · filed 2022-05-12 | $1.00M derived: sum of 2 quarters · filed 2022-05-12 | $1.05M derived: sum of 3 quarters · filed 2022-11-14 | $982.00K derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-12-31 | $1.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $1.32M derived: sum of 2 quarters · filed 2022-11-14 | $1.25M derived: sum of 3 quarters · filed 2022-11-14 | $1.32M 10-K · filed 2022-03-31 | |
| 2021-09-30 | $51.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$22.00K derived: sum of 2 quarters · filed 2022-11-14 | $58.00K 10-Q · filed 2022-11-14 | $1.71M 10-Q · filed 2021-11-12 | $46.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$73.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $7.00K 10-Q · filed 2022-08-15 | -$5.00K derived: sum of 3 quarters · filed 2022-08-15 | -$17.00K derived: sum of 4 quarters · filed 2022-08-15 | |
| 2021-03-31 | $80.00K 10-Q · filed 2022-05-12 | $68.00K derived: sum of 2 quarters · filed 2022-05-12 | $56.00K derived: sum of 3 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$24.00K derived: sum of 2 quarters · filed 2022-03-31 | -$1.00K 10-K · filed 2022-03-31 | ||
| 2020-09-30 | -$12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $11.00K 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | $23.00K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |